

Supplementary Online Content

Ishani A, Hau C, Raju S, et al. Chlorthalidone vs hydrochlorothiazide and kidney outcomes in patients with hypertension: a secondary analysis of a randomized clinical trial. *JAMA Netw Open*. 2024;7(12):e2449576.
doi:10.1001/jamanetworkopen.2024.49576

eFigure 1. Consort Diagram of Patient Flow

eTable 1. CPT Codes Used to Define Dialysis Procedures

eTable 2. Demographic and Baseline Information by Treatment and eGFR Level^a

eFigure 2. Primary Outcome: Time to Doubling of Serum Creatinine, Terminal eGFR < 15 mL/min, or Dialysis Initiation

eFigure 3. Exploratory Outcome: Time to a 40% Reduction in eGFR, Terminal eGFR <15 mL/min, or Dialysis Initiation

eTable 3. Use of Selected Medications Over Time


eFigure 4. Adjusted Subgroup Analysis: Time to Doubling of Serum Creatinine, Terminal eGFR <15 mL/min/1.73m², or Dialysis Initiation

eFigure 5. Unadjusted Subgroup Analysis: Time to > 40% Reduction in eGFR, Terminal eGFR < 15 mL/min/1.73m², or Dialysis Initiation

eTable 4. Safety Outcomes by Treatment and eGFR Level

This supplementary material has been provided by the authors to give readers additional information about their work.

eFigure 1. Consort Diagram of Patient Flow



eTable 1. CPT Codes Used to Define Dialysis Procedures

CPT Codes	
Dialysis	90918, 90919, 90920, 90921, 90922, 90923, 90924, 90925, 90935, 90937, 90939, 90940, 90941, 90942, 90943, 90944, 90945, 90947, 90951, 90952, 90953, 90954, 90955, 90956, 90957, 90958, 90959, 90960, 90961, 90962, 90963, 90964, 90965, 90966, 90967, 90968, 90969, 90970, 90976, 90977, 90978, 90979, 90982, 90983, 90984, 90985, 90988, 90989, 90990, 90991, 90992, 90993, 90994, 90995, 90996, 90997, 90998, 90999

eTable 2. Demographic and Baseline Information by Treatment and eGFR Level^a


	Baseline eGFR ≥ 60 (N = 9,038)		Baseline eGFR < 60 (N = 3,227)	
	CTD (n = 4,520)	HCTZ (n = 4,518)	CTD (n=1,598)	HCTZ (n=1,629)
Age, yrs – median (IQR)	71 (68 – 74)	71 (68 – 74)	73 (70 – 77)	73 (70 – 77)
Body Mass Index, kg/m ² - median (IQR)	31.2 (27.8 – 35.1)	31.3 (27.9 – 35.3)	30.9 (27.7- 34.8)	31.0 (27.9 – 35.0)
Sex				
Female	149 (3.3)	139 (3.1)	49 (3.1)	52 (3.2)
Male	4,371 (96.7)	4,379 (96.9)	1,549 (96.9)	1,577 (96.8)
Race				
Black	704 (15.6)	685 (15.2)	211 (13.2)	237 (14.5)
White	3501 (77.5)	3,514 (77.8)	1,244 (77.8)	1,259 (77.3)
Other ^b	94 (2.1)	96 (2.1)	50 (3.1)	46 (2.8)
Unknown due to missing data	221 (4.9)	223 (4.9)	93 (5.8)	87 (5.3)
Ethnicity				
Hispanic/Latino	164 (3.6)	185 (4.1)	55 (3.4)	60 (3.7)
Not Hispanic/Latino	4,199 (92.9)	4,190 (92.7)	1,482 (92.7)	1,503 (92.3)
Unknown due to missing data	157 (3.5)	143 (3.2)	61 (3.8)	66 (4.1)
Resided in rural areas ^c	2,043 (45.2)	2,074 (45.9)	735 (46.0)	709 (43.5)
Current smoker	1,038 (23.0)	959 (21.2)	347 (21.7)	342 (21.0)
Medical History				
Diabetes	1,865 (41.3)	1,926 (42.6)	898 (56.2)	936 (57.5)
Heart failure	312 (6.9)	295 (6.5)	174 (11.0)	192 (11.8)
Myocardial infarction	146 (3.2)	152 (3.4)	68 (4.3)	80 (4.9)
Stroke	322 (7.1)	294 (6.5)	172 (10.8)	151 (9.3)
Hydrochlorothiazide (HCTZ) 25 mg	4,279 (94.6)	4,266 (94.4)	1,508 (94.4)	1,544 (94.8)
Systolic BP, mm Hg - median (IQR)	139 (131 – 152)	139 (130 – 152)	139 (130 – 152)	139 (130 – 154)
Serum Creatinine, mg/dL - median (IQR)	1.0 (0.9 – 1.1)	1.0 (0.9 – 1.1)	1.4 (1.3 – 1.6)	1.4 (1.3 – 1.6)
Serum Potassium, mg/dL - median (IQR)	4.0 (3.8 – 4.3)	4.0 (3.8 – 4.3)	4.1 (3.9 – 4.5)	4.1 (3.9 – 4.4)
eGFR, ml/min/1.73m ² - median (IQR)	77.5 (68.6 – 89.2)	77.2 (68.3 – 87.3)	50.0 (42.3 – 55.0)	49.8 (42.1 – 55.2)
Antihypertensive drug use				
HCTZ alone	644 (14.2)	633 (14.0)	148 (9.3)	127 (7.8)
HCTZ + 1 additional BP med	1,606 (35.5)	1,584 (35.1)	494 (30.9)	482 (29.6)
HCTZ + 2 additional BP meds	1,454 (32.2)	1,464 (32.4)	535 (33.5)	562 (34.5)
HCTZ + 3 additional BP meds	668 (14.8)	666 (14.7)	316 (19.8)	339 (20.8)
HCTZ + 4 additional BP meds	148 (3.3)	171 (3.8)	105 (6.6)	119 (7.3)
Other drug use				
ACE inhibitor or ARB	2,841 (62.9)	2,844 (62.9)	1,133 (70.9)	1,191 (73.1)
Loop diuretic	73 (1.6)	83 (1.8)	58 (3.6)	74 (4.5)
SGLT-2 inhibitor	110 (2.4)	109 (2.4)	51 (3.2)	61 (3.7)
Spironolactone or Eplerenone	581 (12.9)	601 (13.3)	188 (11.8)	183 (11.2)

^a Data are presented as number(percentage) of patients unless otherwise indicated.


b Included American Indian, Asian, Hawaiian, Pacific Islander, and multiracial.

c Based on Place of residence was defined according to the Veterans Affairs urban, rural, or highly rural classification system.

eFigure 2. Primary Outcome: Time to Doubling of Serum Creatinine, Terminal eGFR < 15 mL/min, or Dialysis Initiation




eFigure 3. Exploratory Outcome: Time to a 40% Reduction in eGFR, Terminal eGFR <15 mL/min, or Dialysis Initiation




eTable 3. Use of Selected Medications Over Time

Baseline eGFR <60 (N=3,227)	Baseline		6 months		12 months		18 months		24 months	
	CTD	HCTZ	CTD	HCTZ	CTD	HCTZ	CTD	HCTZ	CTD	HCTZ
	(n=4,520)	(n=4,518)	(n=4,503)	(n=4,501)	(N=4,014)	(n=4,048)	(n=3,352)	(n=3,366)	(n=2,706)	(n=2,724)
ACE	1,604 (35.5)	1,650 (36.5)	1,555 (34.5)	1,629 (36.2)	1,377 (34.3)	1,448 (35.8)	1,121 (33.4)	1,196 (35.5)	886 (32.7)	934 (34.3)
ARB	1,256 (27.8)	1,209 (26.8)	1,247 (27.7)	1,233 (27.4)	1,119 (27.9)	1,105 (27.3)	949 (28.3)	907 (26.9)	766 (28.3)	728 (26.7)
ACE or ARB	2,841 (62.9)	2,844 (62.9)	2,788 (61.9)	2,844 (63.2)	2,481 (61.8)	2,543 (62.8)	2,052 (61.2)	2,093 (62.2)	1,645 (60.8)	1,655 (60.8)
SGLT2i	110 (2.4)	109 (2.4)	163 (3.6)	160 (3.6)	174 (4.3)	167 (4.1)	161 (4.8)	139 (4.1)	140 (5.2)	138 (5.1)
MRA	581 (12.9)	601 (13.3)	643 (14.3)	650 (14.4)	645 (16.1)	617 (15.2)	542 (16.2)	522 (15.5)	475 (17.6)	446 (16.4)
Loop diuretics	73 (1.6)	83 (1.8)	95 (2.1)	129 (2.9)	130 (3.2)	171 (4.2)	140 (4.2)	176 (5.2)	135 (5.0)	159 (5.8)
Baseline eGFR ≥60 (N=9,038)	Baseline		6 months		12 months		18 months		24 months	
	CTD	HCTZ	CTD	HCTZ	CTD	HCTZ	CTD	HCTZ	CTD	HCTZ
	(n=1,598)	(n=1,629)	(n=1,591)	(n=1,620)	(N=1,412)	(n=1,405)	(n=1,146)	(n=1,160)	(n=888)	(n=885)
ACE	662 (41.4)	675 (41.4)	648 (40.7)	648 (40.0)	577 (40.9)	554 (39.4)	452 (39.4)	447 (38.5)	346 (39.0)	331 (37.4)
ARB	472 (29.5)	525 (26.8)	473 (29.7)	528 (27.4)	414 (29.3)	449 (27.3)	346 (30.2)	377 (26.9)	273 (30.7)	280 (26.7)
ACE or ARB	1,133 (70.9)	1,191 (73.1)	1,115 (70.1)	1,172 (72.3)	985 (69.8)	1,001 (71.2)	791 (69.0)	822 (70.9)	617 (69.5)	63 (7.1)
SGLT2i	51 (3.2)	61 (3.7)	79 (5.0)	97 (6.0)	79 (5.6)	91 (6.5)	66 (5.8)	84 (7.2)	61 (6.9)	107 (12.1)
MRA	188 (11.8)	183 (11.2)	218 (13.7)	192 (11.9)	201 (14.2)	173 (12.3)	156 (13.6)	163 (14.1)	126 (14.2)	126 (14.2)
Loop diuretics	58 (3.6)	74 (4.5)	88 (5.5)	110 (6.8)	105 (7.4)	109 (7.8)	90 (7.9)	116 (10.0)	90 (10.1)	606 (68.5)

eFigure 4. Adjusted Subgroup Analysis: Time to Doubling of Serum Creatinine, Terminal eGFR <15 mL/min/1.73m², or Dialysis Initiation



eFigure 5. Unadjusted Subgroup Analysis: Time to > 40% Reduction in eGFR, Terminal eGFR < 15 mL/min/1.73m², or Dialysis Initiation



eTable 4. Safety Outcomes by Treatment and eGFR Level

	Baseline eGFR \geq 60 (N=9,038)			Baseline eGFR <60 (N=3,227)		
	CTD (n = 4,520)	HCTZ (n = 4,518)	p-value ^a	CTD (n = 1,598)	HCTZ (n = 1,629)	p-value ^a
Safety outcomes						
Hospitalization for acute kidney injury	229 (5.1)	205 (4.5)	0.26	162 (10.1)	174 (10.7)	0.64
Hypokalemia	416 (9.2)	315 (7.0)	<0.001	129 (8.1)	111 (6.8)	0.18
Primary cause of hospitalization	161 (3.6)	123 (2.7)	0.03	52 (3.3)	55 (3.4)	0.92
Potassium lab <3.1 mEq/L	305 (6.8)	226 (5.0)	<0.001	95 (5.9)	67 (4.1)	0.02

^a Computed by Fisher exact test.